Construction of a community-based primary screening and hospital-based confirmatory screening pathway in pediatric nonalcoholic fatty liver disease

构建以社区为基础的儿童非酒精性脂肪肝疾病初筛和以医院为基础的确诊筛查路径

阅读:1

Abstract

BACKGROUND: Fibrosis is a critical event in the progression of pediatric nonalcoholic fatty liver disease (NAFLD). AIM: To develop less invasive models based on machine learning (ML) to predict significant fibrosis in Chinese NAFLD children. METHODS: In this cross-sectional study, 222 and 101 NAFLD children with available liver biopsy data were included in the development of screening models for tertiary hospitals and community health centers, respectively. Predictive factors were selected using least absolute shrinkage and selection operator regression and stepwise logistic regression analyses. Logistic regression (LR) and other ML models were applied to construct the prediction models. RESULTS: Simplified indicators of the ATS and BIU indices were constructed for tertiary hospitals and community health centers, respectively. When models based on the ATS and BIU parameter combinations were constructed, the random forest (RF) model demonstrated higher screening accuracy compared to the LR model (0.80 and 0.79 for the RF model and 0.72 and 0.77 for the LR model, respectively). Using cutoff values of 90% for sensitivity and 90% for specificity, the RF models could effectively identify and exclude NAFLD children with significant fibrosis in the internal validation set (with positive predictive values and negative prediction values exceeding 0.80), which could prevent liver biopsy in 60% and 71.4% of NAFLD children, respectively. CONCLUSION: This study developed new models for predicting significant fibrosis in NAFLD children in tertiary hospitals and community health centers, which can serve as preliminary screening tools to detect the risk population in a timely manner.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。